Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease

David J. Straus, Carol S. Portlock, Jing Qin, Jane Myers, Andrew D. Zelenetz, Craig Moskowitz, Ariela Noy, André Goy, Joachim Yahalom

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

To determine whether combined modality therapy (CMT) is superior to chemotherapy (CT) alone, 152 untreated Hodgkin disease patients with clinical stages (CSs) IA, IB, IIA, IIB, and IIIA without bulk disease were prospectively randomized to 6 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) alone or 6 cycles of ABVD followed by radiation therapy (RT) (3600 cGy: involved field for 11 patients, modified extended field for the rest). Of 76 patients randomized to receive RT, 65 actually received it, and 11 did not (4 progressed, 1 had bleomycin toxicity, 6 refused). For ABVD + RT, the complete remission (CR) percentage was 94% and no major response, 6%. For ABVD alone, 94% achieved a CR; 1.5%, a partial response (PR); and 4.5%, no major response. At 60 months CR duration, freedom from progression (FFP), and overall survival (OS) for ABVD + RT versus ABVD alone are 91% versus 87% (P = .61), 86% versus 81% (P = .61), and 97% versus 90% (P = .08), respectively (log-rank). The 95% confidence intervals for CR duration, FFP, and OS differences at 5 years were -8% to 15%, -8% to 18%, and -4% to 12%, respectively. Although significant differences were not seen, it is possible that a benefit in outcome of less than 20% for CMT might be seen in a larger trial.

Original languageEnglish (US)
Pages (from-to)3483-3489
Number of pages7
JournalBlood
Volume104
Issue number12
DOIs
StatePublished - Dec 1 2004
Externally publishedYes

Fingerprint

Dacarbazine
Vinblastine
Bleomycin
Radiotherapy
Hodgkin Disease
Doxorubicin
Randomized Controlled Trials
Combined Modality Therapy
Chemotherapy
Survival
Toxicity
Confidence Intervals
Drug Therapy

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. / Straus, David J.; Portlock, Carol S.; Qin, Jing; Myers, Jane; Zelenetz, Andrew D.; Moskowitz, Craig; Noy, Ariela; Goy, André; Yahalom, Joachim.

In: Blood, Vol. 104, No. 12, 01.12.2004, p. 3483-3489.

Research output: Contribution to journalArticle

Straus, David J. ; Portlock, Carol S. ; Qin, Jing ; Myers, Jane ; Zelenetz, Andrew D. ; Moskowitz, Craig ; Noy, Ariela ; Goy, André ; Yahalom, Joachim. / Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. In: Blood. 2004 ; Vol. 104, No. 12. pp. 3483-3489.
@article{beadac0d25c046dfb490b2a182fcc44f,
title = "Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease",
abstract = "To determine whether combined modality therapy (CMT) is superior to chemotherapy (CT) alone, 152 untreated Hodgkin disease patients with clinical stages (CSs) IA, IB, IIA, IIB, and IIIA without bulk disease were prospectively randomized to 6 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) alone or 6 cycles of ABVD followed by radiation therapy (RT) (3600 cGy: involved field for 11 patients, modified extended field for the rest). Of 76 patients randomized to receive RT, 65 actually received it, and 11 did not (4 progressed, 1 had bleomycin toxicity, 6 refused). For ABVD + RT, the complete remission (CR) percentage was 94{\%} and no major response, 6{\%}. For ABVD alone, 94{\%} achieved a CR; 1.5{\%}, a partial response (PR); and 4.5{\%}, no major response. At 60 months CR duration, freedom from progression (FFP), and overall survival (OS) for ABVD + RT versus ABVD alone are 91{\%} versus 87{\%} (P = .61), 86{\%} versus 81{\%} (P = .61), and 97{\%} versus 90{\%} (P = .08), respectively (log-rank). The 95{\%} confidence intervals for CR duration, FFP, and OS differences at 5 years were -8{\%} to 15{\%}, -8{\%} to 18{\%}, and -4{\%} to 12{\%}, respectively. Although significant differences were not seen, it is possible that a benefit in outcome of less than 20{\%} for CMT might be seen in a larger trial.",
author = "Straus, {David J.} and Portlock, {Carol S.} and Jing Qin and Jane Myers and Zelenetz, {Andrew D.} and Craig Moskowitz and Ariela Noy and Andr{\'e} Goy and Joachim Yahalom",
year = "2004",
month = "12",
day = "1",
doi = "10.1182/blood-2004-04-1311",
language = "English (US)",
volume = "104",
pages = "3483--3489",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease

AU - Straus, David J.

AU - Portlock, Carol S.

AU - Qin, Jing

AU - Myers, Jane

AU - Zelenetz, Andrew D.

AU - Moskowitz, Craig

AU - Noy, Ariela

AU - Goy, André

AU - Yahalom, Joachim

PY - 2004/12/1

Y1 - 2004/12/1

N2 - To determine whether combined modality therapy (CMT) is superior to chemotherapy (CT) alone, 152 untreated Hodgkin disease patients with clinical stages (CSs) IA, IB, IIA, IIB, and IIIA without bulk disease were prospectively randomized to 6 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) alone or 6 cycles of ABVD followed by radiation therapy (RT) (3600 cGy: involved field for 11 patients, modified extended field for the rest). Of 76 patients randomized to receive RT, 65 actually received it, and 11 did not (4 progressed, 1 had bleomycin toxicity, 6 refused). For ABVD + RT, the complete remission (CR) percentage was 94% and no major response, 6%. For ABVD alone, 94% achieved a CR; 1.5%, a partial response (PR); and 4.5%, no major response. At 60 months CR duration, freedom from progression (FFP), and overall survival (OS) for ABVD + RT versus ABVD alone are 91% versus 87% (P = .61), 86% versus 81% (P = .61), and 97% versus 90% (P = .08), respectively (log-rank). The 95% confidence intervals for CR duration, FFP, and OS differences at 5 years were -8% to 15%, -8% to 18%, and -4% to 12%, respectively. Although significant differences were not seen, it is possible that a benefit in outcome of less than 20% for CMT might be seen in a larger trial.

AB - To determine whether combined modality therapy (CMT) is superior to chemotherapy (CT) alone, 152 untreated Hodgkin disease patients with clinical stages (CSs) IA, IB, IIA, IIB, and IIIA without bulk disease were prospectively randomized to 6 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) alone or 6 cycles of ABVD followed by radiation therapy (RT) (3600 cGy: involved field for 11 patients, modified extended field for the rest). Of 76 patients randomized to receive RT, 65 actually received it, and 11 did not (4 progressed, 1 had bleomycin toxicity, 6 refused). For ABVD + RT, the complete remission (CR) percentage was 94% and no major response, 6%. For ABVD alone, 94% achieved a CR; 1.5%, a partial response (PR); and 4.5%, no major response. At 60 months CR duration, freedom from progression (FFP), and overall survival (OS) for ABVD + RT versus ABVD alone are 91% versus 87% (P = .61), 86% versus 81% (P = .61), and 97% versus 90% (P = .08), respectively (log-rank). The 95% confidence intervals for CR duration, FFP, and OS differences at 5 years were -8% to 15%, -8% to 18%, and -4% to 12%, respectively. Although significant differences were not seen, it is possible that a benefit in outcome of less than 20% for CMT might be seen in a larger trial.

UR - http://www.scopus.com/inward/record.url?scp=9444292843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9444292843&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-04-1311

DO - 10.1182/blood-2004-04-1311

M3 - Article

C2 - 15315964

AN - SCOPUS:9444292843

VL - 104

SP - 3483

EP - 3489

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -